Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck (MRK) ended the recent trading session at $92.25, demonstrating a +1.84% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.59%.

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

COLORADO SPRINGS—Sierra Space has announced pharmaceutical giant Merck as its first commercial rideshare partner for the ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday. The ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...